Nov 29, 2022 12:00PM
Nov 18, 2022 12:00PM
Feb 24, 2022 01:30AM
Sep 24, 2021 02:00AM
Jul 8, 2021 12:00PM
Mar 31, 2021 02:00AM
Feb 12, 2021 02:00AM Lysogene Receives FDA Clearance of Investigational New Drug Application to Initiate the Gene Therapy Clinical Trial in the US with LYS-GM101 for the Treatment of GM1 Gangliosidosis
Sep 25, 2020 02:00AM
Jul 24, 2020 02:00AM
Jun 5, 2020 02:00AM
Apr 22, 2020 01:30AM
Feb 25, 2020 01:30AM
Sep 30, 2019 12:00PM
Apr 11, 2019 01:00AM Lysogene Reports Full Year 2018 Financial Results and Provides Operational Update
Oct 30, 2018 03:00AM
Sep 5, 2018 02:30AM
Aug 1, 2018 10:37AM
Apr 16, 2018 01:45AM
Apr 16, 2018 01:45AM
Mar 26, 2018 12:30PM
Feb 6, 2018 11:45AM Lysogene Gets PIP Green Light from European Medicines Agency on MPS IIIA Pivotal Study; Paving Way for Clinical Trial Application Approvals
Feb 1, 2018 12:30PM
Jan 15, 2018 11:45AM
Dec 21, 2017 11:45AM
Oct 18, 2017 12:00PM
Oct 16, 2017 01:00AM
Oct 4, 2017 12:00PM
Oct 4, 2017 04:00AM Lysogene Announces Company Presentations at October & November Investor Conferences
Sep 19, 2017 11:53AM
Jul 12, 2017 12:30PM
Jul 10, 2017 01:00AM
May 16, 2017 12:00PM
Apr 21, 2017 12:07PM
Apr 12, 2017 12:09PM
Feb 21, 2017 12:00PM Lysogene Receives Orphan Drug Designation from EMA for LYS-GM101 for Treatment of GM1 Gangliosidosis
Feb 2, 2017 01:05PM

324,579 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All